The Scientist

» federal funding and disease/medicine

Most Recent

image: Booger Bacteria’s Sweet Immune Suppression

Booger Bacteria’s Sweet Immune Suppression

By | September 6, 2017

Sweet taste receptor-activating molecules produced by sinus microbes suppress the local innate immune system in humans.

1 Comment

image: Bubbles for Broken Bones

Bubbles for Broken Bones

By | September 1, 2017

Ultrasound-stimulated microbubbles enable gene delivery to fix fractures.

0 Comments

image: Discovery of the Malaria Parasite, 1880

Discovery of the Malaria Parasite, 1880

By | September 1, 2017

Most didn’t believe French doctor Charles Louis Alphonse Laveran when he said he’d spotted the causative agent of the disease—and that it was an animal.

0 Comments

image: Far-Out Science

Far-Out Science

By | September 1, 2017

How psychedelic drugs and infectious microbes alter brain function

0 Comments

image: Decoding the Tripping Brain

Decoding the Tripping Brain

By | September 1, 2017

Scientists are beginning to unravel the mechanisms behind the therapeutic effects of psychedelic drugs.

2 Comments

image: Infographic: The Brain on Psychedelics

Infographic: The Brain on Psychedelics

By | September 1, 2017

Understanding how hallucinogenic drugs affect different neural networks could shed light on their therapeutic potential.

0 Comments

The new technique helped pig tibias heal in just eight weeks.

0 Comments

image: Smoking on a Chip

Smoking on a Chip

By | September 1, 2017

A new device from the Wyss Institute at Harvard University simulates the effects of cigarette smoke on human lungs.

0 Comments

image: Majority of Top Government Science Jobs Unfilled

Majority of Top Government Science Jobs Unfilled

By | August 31, 2017

Only 12 positions out of 44 have received nominations, and half of Trump’s nominees have strong ties to the industries they would oversee, a new report shows.

0 Comments

image: Gilead to Pay Nearly $12B for CAR T-Cell Company

Gilead to Pay Nearly $12B for CAR T-Cell Company

By | August 28, 2017

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

0 Comments

Popular Now

  1. A Newly Identified Species Represents Its Own Eukaryotic Lineage
  2. Telomere Length and Childhood Stress Don’t Always Correlate
  3. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

  4. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

RayBiotech